Fintel reports that on January 30, 2025, B. Riley Securities initiated coverage of Foghorn Therapeutics (NasdaqGM:FHTX) with ...

Learn about the latest financial trends and strategies in our comprehensive article written by a financial expert.

B. Riley issued their Q1 2025 earnings estimates for Customers Bancorp in a research note issued to investors on Monday, ...

B. Riley raised the firm’s price target on Verastem (VSTM) to $9 from $7 and keeps a Buy rating on the shares after speaking with management. The ...

B. Riley analyst Mike Crawford upgraded Redwire (RDW) to Buy from Neutral with a price target of $27, up from $9.50. The firm increased fiscal ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating ...

Research analysts at B. Riley increased their FY2024 earnings estimates for FormFactor in a research note issued on Monday, January 27th. B. Riley analyst C. Ellis now forecasts that the semiconductor ...

Redwire Corp (NYSE:RDW) was upgraded to Buy from Neutral at financial services company B. Riley, which also hiked its price target on the space infrastructure provider to $27.00 from $9.50.

President Donald Trump plans to sign the Laken Riley Act into law as his administration's first piece of legislation.